Skip to main content

Loading market data...

MIRM

Mirum Pharmaceuticals, Inc.

NASDAQ • United states

$83.44

-$1.63

(-1.92%)

Source: Yahoo Finance · Quote time Oct 21, 2026 20:00 GMT+0000

Catalyst Evidence

No verified catalyst stored yet

Click “View” to see the stored chain of evidence (if available).

Management
Credibility
Score

Mirum Pharmaceuticals, Inc. (MIRM)

Unavailable

Quotes may be delayed

$5.42B

Market Cap

646,889

Volume

Unavailable

P/E Ratio

Unavailable

Div Yield

Mirum Pharmaceuticals, Inc. Price Chart

Loading price history…

Management Credibility Analysis

Unavailable

Verified Management Score Unavailable

Management credibility requires sourced guidance and earnings history.

Upcoming Catalysts

Verified event feed

Verified Catalysts Unavailable

No sourced upcoming event feed is configured for this stock yet.

Company profile

No description available

Chief executive: Not disclosed
Headquarters: 989 EAST HILLSDALE BOULEVARD, SUITE 300, FOSTER CITY, CA
Founded: Not disclosed

📈 Company Timeline

Major business events

Positive

Negative

Neutral

13 Oct 2026

Mirum Pharmaceuticals, Inc. reported Another company event

Mirum Pharmaceuticals, Inc. filed an 8-K covering another company event.

28 Sep 2026

Mirum Pharmaceuticals, Inc. reported Another company event

Mirum Pharmaceuticals, Inc. filed an 8-K covering another company event.

8 Sep 2026

Mirum Pharmaceuticals, Inc. reported A director or senior management change or compensation event

Mirum Pharmaceuticals, Inc. filed an 8-K covering a director or senior management change or compensation event.

13 Aug 2026

Large-holder ownership filing

A holder reported or amended a beneficial ownership position of more than 5% in Mirum Pharmaceuticals, Inc..

6 Aug 2026

Large-holder ownership filing

A holder reported or amended a beneficial ownership position of more than 5% in Mirum Pharmaceuticals, Inc..

Capital Structure & Financial Position

Financial strength and liquidity analysis

Cash and equivalents (USD)$330.73M

Total assets (USD)$1.04B

Total liabilities (USD)$1.06B

Shareholders' equity (USD)−$10.42M

Source: SEC EDGAR company facts (opens in a new tab) Balance sheet dated 30 Jun 2026

Peer Comparison - Health Care

Company	Price	Market Cap
LLY - Eli Lilly and Company	$1,276.13 Yahoo Finance	$1.20T
JNJ - Johnson & Johnson	$256.74 Yahoo Finance	$618.71B
ABBV - AbbVie Inc.	$284.80 Yahoo Finance	$503.28B
UNH - UnitedHealth Group Incorporated	$418.43 Yahoo Finance	$375.58B
MRK - Merck & Co., Inc.	$148.55 Yahoo Finance	$366.50B

📋 Corporate Actions

Recent and upcoming corporate events

Verified Corporate Actions Unavailable

Dividend, buyback, split, and spin-off feeds are not ingested for this stock yet.

Financials

Financial statements and key metrics analysis

Quarter	Revenue (USD)	Operating income	Net income	Diluted EPS (USD)	Filed
Q2 2026	$176.24M	−$42.54M	−$67.23M	−$1.06	10-Q · 5 Aug 2026
Q1 2026	$159.88M	−$789.47M	−$790.16M	−$13.43	10-Q · 6 May 2026
Q4 2025	$148.93M	−$4.57M	−$5.73M	Unavailable	10-K · 25 Feb 2026
Q3 2025	$133.01M	$2.60M	$2.91M	$0.05	10-Q · 4 Nov 2025
Q2 2025	$127.79M	−$4.99M	−$5.86M	−$0.12	10-Q · 6 Aug 2025
Q1 2025	$111.59M	−$15.18M	−$14.68M	−$0.30	10-Q · 7 May 2025

Source: SEC EDGAR company facts (opens in a new tab)

Analyst Consensus

Buy

Target: $154.45

85.1% upside potential

📈

Strong Buy

Unavailable

👍

Buy

12

⏸️

Hold

0

📉

Sell

0

12 analysts covering this stock

Source: Nasdaq analyst research (opens in a new tab) Retrieved 21 Oct 2026, 21:48 UTC Targets range 130.00–200.00 Ratings are third-party opinions, not advice.

💰 Upcoming Dividends

Next dividend payments

Verified Dividend Data Unavailable

Dividend calendar data is not ingested for this stock yet.

Guidance Evolution

Verified Guidance History Unavailable

Verified company guidance history is not ingested for this stock yet.

💼 Director Transactions

Recent insider activity

16

Oct 2026

Howe Jolanda

SVP, GLOBAL CONTROLLER

Option exercise

$19.24 per share

16,112 shares

6

Oct 2026

Peetz Christopher

Director, CHIEF EXECUTIVE OFFICER

Option exercise

$17.31 per share

12,197 shares

14

Sep 2026

BJERKHOLT ERIC

CHIEF FINANCIAL OFFICER

Open-market sale

$98.37 per share

9,943 shares

11

Sep 2026

BJERKHOLT ERIC

CHIEF FINANCIAL OFFICER

Option exercise

Unavailable per share

18,333 shares

2

Sep 2026

Howe Jolanda

SVP, GLOBAL CONTROLLER

Open-market sale

$100.00 per share

658 shares

1

Sep 2026

Peetz Christopher

Director, CHIEF EXECUTIVE OFFICER

Option exercise

$2.94 per share

30,000 shares

1

Sep 2026

Peetz Christopher

Director, CHIEF EXECUTIVE OFFICER

Open-market sale

$98.68 per share

30,000 shares

18

Aug 2026

Howe Jolanda

SVP, GLOBAL CONTROLLER

Option exercise

$6.27 per share

40,000 shares

18

Aug 2026

Howe Jolanda

SVP, GLOBAL CONTROLLER

Open-market sale

$100.00 per share

40,000 shares

11

Aug 2026

BJERKHOLT ERIC

CHIEF FINANCIAL OFFICER

Open-market sale

$99.90 per share

6,001 shares

Top Shareholders

Frazier Life Sciences Management, L.P.

7,679,684 shares

0% change

6/30/2026

Janus Henderson Group Ltd.

6,945,813 shares

14.517% change

3/31/2026

Jupiter Topco Llc

5,909,184 shares

New% change

6/30/2026

Blackrock, Inc.

4,390,063 shares

14.13% change

6/30/2026

Fmr Llc

3,670,314 shares

86.749% change

6/30/2026

Price T Rowe Associates Inc /Md/

2,655,607 shares

54.628% change

6/30/2026

Vanguard Group Inc

2,596,089 shares

1.993% change

12/31/2025

Vanguard Portfolio Management Llc

2,377,019 shares

65.983% change

6/30/2026

Vanguard Capital Management Llc

2,254,109 shares

-6.653% change

6/30/2026

State Street Corp

2,170,689 shares

11.645% change

6/30/2026

Source: Nasdaq institutional holdings (opens in a new tab) Observed 21 Oct 2026, 21:48 UTC· 8 hours ago

Research coverage and investment tools

Mirum Pharmaceuticals, Inc. (MIRM) is a stock listed on the Nasdaq in the United States, in the Health Care sector (Biotechnology: Pharmaceutical Preparations). Its last price was US$83.44 on 21 Oct 2026. That is 30% of the way from its 52-week low of US$63.23 to its 52-week high of US$130.00. Its market capitalisation was US$5.42 billion at that price.

Watch Add to portfolio Set an alert Compare Position size

How position sizing works Dividend yield and total return

Quarter	Revenue	Operating income	Net income	Diluted EPS	Gross margin	Operating margin	Free cash flow	Filed
Q2 2026	$176.24M	−$42.54M	−$67.23M	−$1.06	—	-24.1%	−$44.28M	10-Q · 5 Aug 2026 (opens in a new tab)
Q1 2026	$159.88M	−$789.47M	−$790.16M	−$13.43	—	-493.8%	−$229.43M	10-Q · 6 May 2026 (opens in a new tab)
Q4 2025	$148.93M	−$4.57M	−$5.73M	Unavailable	—	-3.1%	$5.47M	10-K · 25 Feb 2026 (opens in a new tab)
Q3 2025	$133.01M	$2.60M	$2.91M	$0.05	—	2.0%	$39.49M	10-Q · 4 Nov 2025 (opens in a new tab)
Q2 2025	$127.79M	−$4.99M	−$5.86M	−$0.12	—	-3.9%	$11.91M	10-Q · 6 Aug 2025 (opens in a new tab)
Q1 2025	$111.59M	−$15.18M	−$14.68M	−$0.30	—	-13.6%	−$2.00M	10-Q · 7 May 2025 (opens in a new tab)

Quarter ended	Reported	EPS	Consensus	Surprise
Jun 2026	8/5/2026	−$0.80	−$0.77	-3.9%
Mar 2026	5/6/2026	−$0.39	−$0.40	+2.5%
Dec 2025	2/25/2026	−$0.11	$0.02	-650.0%
Sep 2025	11/4/2025	$0.05	−$0.10	+150.0%

Cash and equivalents: $330.73M
Total assets: $1.04B
Total liabilities: $1.06B
Shareholders' equity: −$10.42M

8-K · 13 Oct 2026

Mirum Pharmaceuticals, Inc. reported Another company event (opens in a new tab)

Mirum Pharmaceuticals, Inc. filed an 8-K covering another company event.
8-K · 28 Sep 2026

Mirum Pharmaceuticals, Inc. reported Another company event (opens in a new tab)

Mirum Pharmaceuticals, Inc. filed an 8-K covering another company event.
8-K · 8 Sep 2026 · Management change

Mirum Pharmaceuticals, Inc. reported A director or senior management change or compensation event (opens in a new tab)

Mirum Pharmaceuticals, Inc. filed an 8-K covering a director or senior management change or compensation event.
SCHEDULE 13G/A · 13 Aug 2026

Large-holder ownership filing (opens in a new tab)

A holder reported or amended a beneficial ownership position of more than 5% in Mirum Pharmaceuticals, Inc..
SCHEDULE 13G · 6 Aug 2026

Large-holder ownership filing (opens in a new tab)

A holder reported or amended a beneficial ownership position of more than 5% in Mirum Pharmaceuticals, Inc..

Insider	Date	Transaction	Shares	Average price	Filing
Howe Jolanda SVP, GLOBAL CONTROLLER	16 Oct 2026	Option exercise (M)	+16,112	$19.24	Form 4 (opens in a new tab)
Peetz Christopher Director, CHIEF EXECUTIVE OFFICER	6 Oct 2026	Option exercise (M)	+12,197	$17.31	Form 4 (opens in a new tab)
BJERKHOLT ERIC CHIEF FINANCIAL OFFICER	14 Sep 2026	Open-market sale (S)	−9,943	$98.37	Form 4 (opens in a new tab)
BJERKHOLT ERIC CHIEF FINANCIAL OFFICER	11 Sep 2026	Option exercise (M)	+18,333	—	Form 4 (opens in a new tab)
Howe Jolanda SVP, GLOBAL CONTROLLER	2 Sep 2026	Open-market sale (S)	−658	$100.00	Form 4 (opens in a new tab)
Peetz Christopher Director, CHIEF EXECUTIVE OFFICER	1 Sep 2026	Option exercise (M)	+30,000	$2.94	Form 4 (opens in a new tab)
Peetz Christopher Director, CHIEF EXECUTIVE OFFICER	1 Sep 2026	Open-market sale (S)	−30,000	$98.68	Form 4 (opens in a new tab)
Howe Jolanda SVP, GLOBAL CONTROLLER	18 Aug 2026	Option exercise (M)	+40,000	$6.27	Form 4 (opens in a new tab)
Howe Jolanda SVP, GLOBAL CONTROLLER	18 Aug 2026	Open-market sale (S)	−40,000	$100.00	Form 4 (opens in a new tab)
BJERKHOLT ERIC CHIEF FINANCIAL OFFICER	11 Aug 2026	Open-market sale (S)	−6,001	$99.90	Form 4 (opens in a new tab)

Institution	Report date	Shares	Change
Frazier Life Sciences Management, L.P.	6/30/2026	7,679,684	0%
Janus Henderson Group Ltd.	3/31/2026	6,945,813	14.517%
Jupiter Topco Llc	6/30/2026	5,909,184	New
Blackrock, Inc.	6/30/2026	4,390,063	14.13%
Fmr Llc	6/30/2026	3,670,314	86.749%
Price T Rowe Associates Inc /Md/	6/30/2026	2,655,607	54.628%
Vanguard Group Inc	12/31/2025	2,596,089	1.993%
Vanguard Portfolio Management Llc	6/30/2026	2,377,019	65.983%
Vanguard Capital Management Llc	6/30/2026	2,254,109	-6.653%
State Street Corp	6/30/2026	2,170,689	11.645%

Previous close: 85.07 USD
Day range: 82.86 – 85.84 USD
52-week range: 63.23 – 130.00 USD
Volume: 646,889
Market cap: $5.42B
Average volume: 686,795
EPS (FY 2025, diluted): −0.47 USD
Shares outstanding: 64.93M
Beta (5Y monthly): 0.73

Price, ranges and volume: Yahoo Finance (opens in a new tab) Observed 21 Oct 2026, 20:00 UTC· 10 hours ago

Average volume, P/E and shares: Nasdaq (opens in a new tab) Observed 22 Oct 2026, 06:32 UTC· 1 minute ago

EPS: SEC EDGAR company facts (opens in a new tab)

Beta: 5 years of monthly returns against the S&P 500, calculated from Yahoo Finance prices. Market cap is the price × shares outstanding.

This research is not available for MIRM yet

Guidance history

IMPORTANT FINANCIAL DISCLAIMER: The information provided on this platform is for educational and informational purposes only and should not be construed as investment advice. All investments involve risk, including potential loss of principal. Past performance does not guarantee future results. Take Profits is not a registered investment advisor and does not provide personalized investment advice. Users should conduct their own research and consult with qualified financial professionals before making investment decisions. Market data may be delayed and is provided by third-party sources.